Immune checkpoints could be key to treating autoimmune disease myasthenia gravis

November 30, 2018, Kanazawa University
MHC class I and PD-L1 expression in the muscle tissue, as detected by immunohistochemistry. MHC class I and PD-L1 expression was upregulated in the sarcolemmal and sarcoplasmic regions in patients with myositis and myasthenia gravis. There was no overexpression of MHC class I and PD-L1 in muscle tissues obtained from patients with non-myopathy. Credit: Kanazawa University

Quite literally meaning "grave muscle weakness," myasthenia gravis is a chronic autoimmune disorder that causes serious weakening of skeletal muscles responsible for movements such as ocular motion, eye-opening, swallowing, and breathing. Although symptoms can be controlled, there is currently no cure for this potentially debilitating disease.

In normal muscle tissues, movement is triggered when release a neurotransmitter called acetylcholine, which binds to a receptor on muscle cells. This binding activates the muscle and causes it to contract. Myasthenia gravis occurs when the —which usually protects us from invading pathogens—mistakenly attacks the acetylcholine receptors needed for muscle movement. Controlling the is therefore key to treating .

Bearing this in mind, researchers at Kanazawa University investigated whether pathways that regulate the immune response, known as immune checkpoints, could be harnessed for the treatment of myasthenia gravis. The findings are published in a recent issue of the Journal of Neuroimmunology. Lead author Kazuo Iwasa describes the rationale behind the study: "Inhibitory checkpoint molecule programmed 1 (PD-1) and its ligands, PD-L1 and PD-L2, inhibit T-cell signaling and are extremely important for immunotolerance. Disruption of this pathway has been implicated in other autoimmune disorders, but its role in myasthenia gravis is unclear."

qRT-PCR analysis of PD-L1 mRNA levels in muscle cells. Relative PD-L1 mRNA expression levels were significantly increased in patients with myasthenia gravis (MG) and myositis when compared to those in patients with non-myopathy (NM) (MG vs. NM p < 0.05, myositis vs. NM p < 0.005). Credit: Kanazawa University

Using a specific fluorescent antibody, or marker, that binds to PD-L1, the research team showed that the ligand was more abundant in muscle tissues collected from myasthenia gravis patients compared with muscles from healthy individuals. Studying gene expression in these tissues confirmed their initial findings, with results showing that the PD-L1 gene was more highly expressed in patient tissues. Importantly, there was no difference between male and female patients, and gene expression was not influenced by the presence of tumors in the thymus, the organ responsible for the maturation of T-cells. However, there did appear to be a reciprocal association between PD-L1 gene expression and disease severity.

"The unimodal relationship between PD-L1 and disease severity was particularly enlightening," says study corresponding author Masahito Yamada. "As disease severity increases, so does PD-L1 expression in , which may influence autoimmune reactivity and help to reduce or stabilize disease severity. Knowing this, we can potentially develop therapies targeting the PD-1 pathway to eliminate the symptoms of myasthenia gravis."

General additive model of quantitative myasthenia gravis scores for disease severity (QMG score) and PD-L1 mRNA expression in the skeletal muscle. Relative PD-L1 mRNA levels showed a unimodally distributed correlation with QMG score. Credit: Kanazawa University

Explore further: New research finds pathogenic connection between autoimmune disorders and cancer

More information: Kazuo Iwasa et al, Programmed cell death ligand 1 expression is upregulated in the skeletal muscle of patients with myasthenia gravis, Journal of Neuroimmunology (2018). DOI: 10.1016/j.jneuroim.2018.09.012

Related Stories

New research finds pathogenic connection between autoimmune disorders and cancer

July 22, 2014
Autoimmune disorders may share certain pathogenic mechanisms with cancer, according to a new report by George Washington University (GW) researcher Linda Kusner, Ph.D., published in PLOS ONE on July 22.

Study explains why myasthenia patients relapse after treatment

September 8, 2017
A new Yale-led study helps explain why some myasthenia gravis (MG) patients relapse after initially responding to a drug called rituximab, commonly used to treat the incurable autoimmune disease marked by muscle weakness ...

Scientists make first crystal model of under-diagnosed autoimmune disease

June 13, 2017
As a molecular biologist, Kaori Noridomi gets an up-close view of the targets of her investigations. But when she began studying the molecular structures of a rarely diagnosed autoimmune disorder, myasthenia gravis, she decided ...

Treating myasthenia gravis with autologous hematopoietic stem cell transplants

April 4, 2016
A report on seven cases of severe myasthenia gravis (an autoimmune disease characterized by severe muscle weakness) suggests that autologous hematopoietic stem cell transplantation (when a patient's own stem cells are used) ...

New cause found for muscle-weakening disease myasthenia gravis

November 11, 2013
An antibody to a protein critical to enabling the brain to talk to muscles has been identified as a cause of myasthenia gravis, researchers report.

Researchers halt autoimmune disease myasthenia gravis in mice

October 1, 2012
Working with mice, Johns Hopkins researchers say they have developed a gene-based therapy to stop the rodent equivalent of the autoimmune disease myasthenia gravis by specifically targeting the destructive immune response ...

Recommended for you

Exercise-induced hormone irisin triggers bone remodeling in mice

December 13, 2018
Exercise has been touted to build bone mass, but exactly how it actually accomplishes this is a matter of debate. Now, researchers show that an exercise-induced hormone activates cells that are critical for bone remodeling ...

Law professor suggests a way to validate and integrate deep learning medical systems

December 13, 2018
University of Michigan professor W. Nicholson Price, who also has affiliations with Harvard Law School and the University of Copenhagen Faculty of Law, suggests in a Focus piece published in Science Translational Medicine, ...

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Pain: Perception and motor impulses arise in brain independently of one another

December 13, 2018
Pain is a negative sensation that we want to get rid of as soon as possible. In order to protect our bodies, we react by withdrawing the hand from heat, for example. This action is usually understood as the consequence of ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Researchers give new insight to muscular dystrophy patients

December 13, 2018
New research by University of Minnesota scientists has revealed the three-dimensional structure of the DUX4 protein, which is responsible for the disease, facioscapulohumeral muscular dystrophy (FSHD). Unlike the majority ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.